NASDAQ: PLRZ) Soars as Superior Mucoadhesion Naloxone Hydrogel Signals Stronger Real-World Opioid Overdose Reversal Potential" src="https://www.abnewswire.com/upload/2025/12/1764846072.jpg" alt="Polyrizon (NASDAQ: PLRZ) Soars as Superior Mucoadhesion Naloxone Hydrogel Signals Stronger Real-World Opioid Overdose Reversal Potential" width="225" height="225">Active Stocks Releasing News Recently to Watch Now: Myseum, Inc. (NASDAQ: MYSE), SurgePays, Inc. (NASDAQ: SURG), ENDRA Life Sciences (NASDAQ: NDRA), Scienjoy Corp (NASDAQ: SJ), Roadzen Inc (NASDAQ: RZDN), Kartoon Studios, Inc (NYSE: TOON), Power Metallic Mines (TSX-V: PNPN | OTCQB: PNPNF), Synergy CHC Corp. (NASDAQ: SNYR),Datavault AI (NASDAQ: DVLT) and Peraso Inc (NASDAQ: PRSO) — all active in trading sessions and should be added to your radar now as momentum accelerates across the small-cap biotech, tech, media and AI sectors.
Polyrizon Ltd. (Nasdaq: PLRZ) soars in after-hours and pre-market trading after announcing powerful new preclinical data demonstrating that its proprietary intranasal naloxone hydrogel exhibits significantly superior mucoadhesion compared to a marketed intranasal naloxone spray yesterday — a critical performance advantage for real-world opioid overdose emergencies.
Using an established ex-vivo rabbit nasal mucosa model, researchers compared the persistence of Polyrizon’s hydrogel to a commercial naloxone product under repeated washing with Simulated Nasal Electrolyte Solution (SNES). Polyrizon’s Trap & Target™ (T&T) hydrogel retained dramatically higher fluorescence levels, with results reaching p < 0.0001, demonstrating far stronger and more durable mucosal adhesion.
Enhanced mucoadhesion is a key driver of intranasal drug delivery performance — particularly for emergency opioid overdose reversal — because increased nasal residence time supports more reliable absorption and potentially faster onset of action.
“These results further validate the potential of our T&T hydrogel platform,” said Tomer Izraeli, CEO of Polyrizon. “Outperforming a marketed product in mucoadhesion is a significant milestone for our Naloxone program.”
The new findings build on Polyrizon’s previously reported stability data, reinforcing the Company’s positioning in intranasal drug delivery, biodefense, and next-generation hydrogel-based therapeutics. With global opioid overdose deaths continuing to rise, Polyrizon’s innovation may represent a meaningful improvement in emergency response tools.
Investors now anticipate next steps including preclinical advancement, regulatory pathway updates, and future clinical development as Polyrizon moves toward what could become a best-in-class intranasal naloxone product. For more information, visit www.polyrizon-biotech.com.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
